7 recruiting, 4 completed, 2 active not recruiting, 1 terminated. 9 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 3.
Follow Allogeneic HSCT: new trials by email Literature Review of Allogeneic HSCT trials Research Report on Allogeneic HSCT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL Olverembatinib, Gecacitinib, Venetoclax - Ph-Like, Acute Lymphoblastic Leukemia | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 92 | 2026-05-30 | 2026-05-13 |
| A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF) - Immunodeficiency, Hematopoietic Stem Cell Transplantation | Phase 2 | Recruiting | National Cancer Institute (NCI) | 54 | 2023-02-23 | 2026-10-16 |
| The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation Melphalan, Sirolimus, Total Body Irradiation (TBI) - Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 260 | 2022-11-18 | 2026-10-16 |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2021-09-23 | 2026-10-16 |
| A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. Cytarabine, Busulfan, Cyclophosphamide - Leukemia, Graft-versus-host-disease | Phase 2 | Unknown | Yi Luo | 46 | 2020-12-03 | 2023-02-21 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Busulfan test dose, Fludarabine, Busulfan - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2020-09-22 | 2026-10-19 |
| A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies Cytarabine, Busulfan, Cyclophosphamide - Leukemia, MDS | Phase 3 | Active not recruiting | First Affiliated Hospital of Zhejiang University | 232 | 2020-09-01 | 2026-04-09 |
| Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL CD19/CD22 CAR-T - B-ALL | Phase 1 / Phase 2 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 50 | 2020-07-27 | 2023-02-22 |
| Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults Pediatric-type of chemotherapy, allogeneic HSCT - Acute Lymphoblastic Leukemia | Not applicable | Recruiting | PETHEMA Foundation | 300 | 2019-11-25 | 2022-02-18 |
| Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+ Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT), Consolidation with auto-HSCT or HLA-matched HSCT, allogeneic HSCT - Acute Myeloid Leukemia, Risk Stratification | Not applicable | Completed | Nanfang Hospital, Southern Medical University | 207 | 2016-10-01 | 2023-08-08 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) Allogeneic HSCT, Fludarabine, Melphalan - Multiple Myeloma | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 57 | 2015-08-01 | 2023-01-04 |
| Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations Allogeneic HSCT, Busulfan Test dose, Fludarabine (Fludara, Berlex Laboratories) - GATA2, Immunodeficiency | Phase 2 | Recruiting | National Cancer Institute (NCI) | 144 | 2013-07-24 | 2026-10-16 |
| Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS Vincristine in induction, Daunorubicin in induction, Prednisone in induction - Acute Lymphoblastic Leukemia | Completed | PETHEMA Foundation | 418 | 2012-02-01 | 2020-03-09 | |
| Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP) - Leukemia, Myeloid, Leukemia | Phase 3 | Terminated | Stanford University | 58 | 2007-08-01 | 2019-09-24 |
| Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT allogeneic HSCT - Multiple Myeloma | Phase 2 | Completed | Universitätsklinikum Hamburg-Eppendorf | 50 | 2002-11-01 | 2022-09-02 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Leukemia (3) · Leukemia, Myeloid, Acute (3) · Autoimmune Diseases (2) · Hematologic Neoplasms (2) · Immunologic Deficiency Syndromes (2) · Multiple Myeloma (2) · Anemia, Refractory, with Excess of Blasts (1) · Bronchiolitis Obliterans Syndrome (1) · Common Variable Immunodeficiency (1) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Immune System Diseases (1) · Leukemia, Myeloid (1) · Lymphoproliferative Disorders (1)
National Cancer Institute (NCI) (5) · PETHEMA Foundation (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · First Affiliated Hospital of Zhejiang University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Nanfang Hospital, Southern Medical University (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Stanford University (1) · Universitätsklinikum Hamburg-Eppendorf (1) · Yi Luo (1)
United States (7) · China (3) · Spain (2) · Germany (1) · Russia (1)
Christopher G Kanakry, M.D. (2) · Bhavisha A Patel, M.D. (1) · Dan Xu (1) · Danielle E Pregent-Arnold, M.D. (1) · Mary Horowitz, MD (1) · Michael Maschan (1) · Nicolaus Kroeger, Prof. Dr. (1) · Robert Lowsky (1) · Sung-Yun Pai, M.D. (1) · Yi Luo (1) · Yi Luo, MD (1)
PMID 19912215, PMID 32556286, PMID 33150388, PMID 35840087, PMID 36251488, PMID 37595058, PMID 37957175, PMID 41175032, PMID 41370196, PMID 42081455
U01HL069294 (1)